Drug Profile
BZL 101
Alternative Names: Bezielle; BZL-101Latest Information Update: 20 Jan 2016
Price :
$50
*
At a glance
- Originator Bionovo
- Class Antineoplastics; Phytotherapies
- Mechanism of Action Apoptosis stimulants; Glycolysis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Pancreatic cancer
Most Recent Events
- 12 Mar 2012 No development reported - Preclinical for Pancreatic cancer in USA (PO)
- 06 Feb 2012 Bionovo plans a phase II trial for Breast cancer in USA (NCT00907959)
- 02 Nov 2010 Bionovo receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA) for controlled-release BZL 101 development in Breast cancer